Raymond James analyst Jayson Bedford lowered price target on $JNJ to $153 from $161 &amp; keeps an Outperform rating. He believes J&amp;J's Pharma &amp; Consumer segments should be relatively insulated in the coronavirus era, &amp; says the co's portfolio is better positioned than most